Skip to main navigation

Skip to main content

Home

Home

About

About Liquidia

Products and Pipeline

Pipeline and Products

IR Nav

Investors

Careers

Careers
- Overview
- Jobs
- Benefits
- Core Values

Contact Us

Contact Us
- Overview
- Map/Directions

Events & Presentations

IR Nav

Investors

Overview
Press Releases
Events & Presentations
Stock Information
Analyst Coverage Stock Quote & Chart Historical Price Lookup Investment Calculator
Corporate Governance
Documents & Charters Leadership Board of Directors Committee Composition
SEC Filings
IR Resources
Investor FAQs IR Contact Email Alerts Proxy Online

Events & Presentations

Upcoming Events

More events are coming soon.

Past Events

43rd Annual J.P. Morgan Healthcare Conference

Jan 15, 2025 at 12:45 PM EST

Click here for webcast

J.P. Morgan Healthcare Conference Presentation 1.6 MB

Stifel 2024 Healthcare Conference

Nov 19, 2024 at 3:00 PM EST

Click here for webcast

Liquidia Third Quarter 2024 Financial Results and Corporate Update Call

Nov 13, 2024 at 8:30 AM EST

Listen to Webcast

Liquidia Second Quarter 2024 Financial Results and Corporate Update Call

Aug 7, 2024 at 8:30 AM EDT

Click here for webcast

Liquidia First Quarter 2024 Financial Results and Corporate Update Call

May 14, 2024 at 8:30 AM EDT

Click here for webcast

Liquidia Full Year 2023 Financial Results and Corporate Update Call

Mar 13, 2024 at 8:30 AM EDT

Click here for webcast

IR Tools

Print Page
Share
RSS

Request Email Alerts

419 Davis Drive, Suite 100, Morrisville, NC 27560
Tel +1 919-328-4400
Fax +1 919-328-4402

Socials

© 2025 Liquidia Corporation All Rights Reserved.

Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit https://www.liquidia.com.

Legal Nav

Legal
Privacy
Cookies
Social Media

Facebook
Twitter
LinkedIn